#Inform diagnostics financials pdf#
#Inform diagnostics financials full#

We use a cookie to administrate our cookie banner as well as other essential cookies which are necessary for the website to function properly (“ essential cookies”). There is plenty to read about cookies and how they work online. Our use of cookies may include processing of your personal data and we therefore recommend that you read our Privacy Policy, which can be found here privacy policy. In short: they ensure you do not have to select the same preferences over again every time you visit a website. Usually, cookies carry identification on the source, a timestamp for expiry, and a scrambled settings value.Ĭookies work like your browser’s memory – they enable your device to remember settings in between sessions, such as items stored in the cart, language settings and currency preferences. Information about cookies BOULE DIAGNOSTICS AB (PUBL) Generalīoule Diagnostics AB (publ) (“ Boule”) uses cookies and similar technologies (jointly called “cookies”) which are text files placed on your computer, to collect standard Internet log information and visitor behavior information in an anonymous form. The information was submitted for publication, through the agency of the contact person set out above, at 14.15 CET on April 14, 2022. This information is information that Boule Diagnostics AB is obliged to make public pursuant to the Securities Market Act. The Boule shares are listed on Nasdaq Stockholm since 2011. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90Īnnette Colin, CFO, Boule Diagnostics AB, phone +46 (0)70-319 06 76īoule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The annual report will also be made available in English at at a later date, in time for the Annual General Meeting on at the latest.

#Inform diagnostics financials pdf#

The annual report is available in Swedish below as a PDF and in the European Single Electronic Format (ESEF), printed copies of the Swedish version will be available to shareholders upon request by late April.

#Inform diagnostics financials full#

Burgstahler’s extensive experience serving as a director for a diverse group of private and public companies, including those in the healthcare industry, makes him well-qualified to serve as a member of our board of directors.Boule Diagnostics AB has published the full Swedish annual report for the fiscal year 2021 at. in Aerospace Engineering from the University of Kansas and an M.B.A. Burgstahler also previously served on the board of directors of AngioDynamics (NASDAQ: ANGO), Armored AutoGroup, BioReliance Corp., ConvaTec Group, Focus Diagnostics, Inc., INC Research Holdings (NASDAQ: INCR), Lantheus Holdings, MPI Research, Inc., Strategic Partners, LLC, Visant Corp., WideOpenWest (NYSE: WOW) and Warner Chilcott PLC (NASDAQ: WCRX). He currently serves as on the board of directors of Arcadia Consumer Healthcare, Cosette Pharmaceuticals, Inform Diagnostics, Osmotica Pharmaceuticals (NASDAQ: OSMT), United BioSource Corporation, XIFIN and other private company boards. Burgstahler worked at Andersen Consulting (now known as Accenture) and McDonnell Douglas (now known as Boeing). Prior to forming Avista, he was a Partner of DLJMB from 2004 to 2005 and served in various capacities at DLJMB and its affiliates from 1995 to 2005. Burgstahler is a Managing Partner and Co-Chief Executive Officer of Avista and has served in various capacities at Avista since its founding in 2005. David Burgstahler has been a Director since our inception and our President and Chief Executive Officer since February 12, 2021.